Tags

Type your tag names separated by a space and hit enter

Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
J Viral Hepat 2016; 23(12):971-976JV

Abstract

There is little data on the long-term follow-up outcomes of chronic hepatitis C patients achieving sustained virological response (SVR) after treatment with peglylated interferon-α plus ribavirin. We prospectively investigated the overall clinical, biochemical, virological and histological outcomes in a ten-year cohort study of 325 patients with chronic hepatitis C achieving SVR to pegylated interferon-α and ribavirin therapy. Patients underwent consistent clinical, biochemical and virological evaluation every six months, and patients with pretherapy Ishak fibrosis score ≥2 were invited to accept a second liver biopsy at the last follow-up. Liver biopsy specimens were evaluated using Ishak's scoring system. At the end of follow-up, five patients developed decompensated liver cirrhosis. One patient (0.3%) with pretherapy cirrhosis was diagnosed with hepatocellular carcinoma (HCC). A total of 305 patients (94%) had normal serum ALT and AST levels during the entire period of follow-up. Twenty-seven patients (8%) had conclusive evidence of virological relapse. Among the 117 patients with paired pretherapy and long-term follow-up biopsies, 96 (82%) had a decreased fibrosis score. Ninety-nine (79%) had a decrease in combined inflammation score. Thirty-seven (32%) had normal or nearly normal livers on long-term follow-up biopsy. SVR achieved with PEG-IFN-α and RBV combination therapy is durable, while late virological relapse may still occur in some patients. Clinical outcomes for patients who obtain SVR are excellent, although the patients with cirrhosis are still at a low risk of hepatocellular carcinoma.

Authors+Show Affiliations

Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Infectious Diseases, Linyi People's Hospital, Linyi, Shandong, China.Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Infectious Diseases, The Affiliated Hospital of Putian University, Putian, Fujian, China.Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27453300

Citation

Wang, X, et al. "Ten-year Follow-up Analysis of Chronic Hepatitis C Patients After Getting Sustained Virological Response to Pegylated Interferon-α and Ribavirin Therapy." Journal of Viral Hepatitis, vol. 23, no. 12, 2016, pp. 971-976.
Wang X, Gao F, Yuan G, et al. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. J Viral Hepat. 2016;23(12):971-976.
Wang, X., Gao, F., Yuan, G., Shi, K., Huang, Y., Chen, Y., ... Zhou, Y. (2016). Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. Journal of Viral Hepatitis, 23(12), pp. 971-976. doi:10.1111/jvh.12574.
Wang X, et al. Ten-year Follow-up Analysis of Chronic Hepatitis C Patients After Getting Sustained Virological Response to Pegylated Interferon-α and Ribavirin Therapy. J Viral Hepat. 2016;23(12):971-976. PubMed PMID: 27453300.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. AU - Wang,X, AU - Gao,F, AU - Yuan,G, AU - Shi,K, AU - Huang,Y, AU - Chen,Y, AU - Qiu,R, AU - Sun,L, AU - Liu,J, AU - Hu,C, AU - Zhou,Y, Y1 - 2016/07/24/ PY - 2016/04/17/received PY - 2016/07/07/accepted PY - 2016/7/28/pubmed PY - 2017/10/31/medline PY - 2016/7/26/entrez KW - chronic hepatitis C KW - cohort study KW - long term KW - sustained virological response SP - 971 EP - 976 JF - Journal of viral hepatitis JO - J. Viral Hepat. VL - 23 IS - 12 N2 - There is little data on the long-term follow-up outcomes of chronic hepatitis C patients achieving sustained virological response (SVR) after treatment with peglylated interferon-α plus ribavirin. We prospectively investigated the overall clinical, biochemical, virological and histological outcomes in a ten-year cohort study of 325 patients with chronic hepatitis C achieving SVR to pegylated interferon-α and ribavirin therapy. Patients underwent consistent clinical, biochemical and virological evaluation every six months, and patients with pretherapy Ishak fibrosis score ≥2 were invited to accept a second liver biopsy at the last follow-up. Liver biopsy specimens were evaluated using Ishak's scoring system. At the end of follow-up, five patients developed decompensated liver cirrhosis. One patient (0.3%) with pretherapy cirrhosis was diagnosed with hepatocellular carcinoma (HCC). A total of 305 patients (94%) had normal serum ALT and AST levels during the entire period of follow-up. Twenty-seven patients (8%) had conclusive evidence of virological relapse. Among the 117 patients with paired pretherapy and long-term follow-up biopsies, 96 (82%) had a decreased fibrosis score. Ninety-nine (79%) had a decrease in combined inflammation score. Thirty-seven (32%) had normal or nearly normal livers on long-term follow-up biopsy. SVR achieved with PEG-IFN-α and RBV combination therapy is durable, while late virological relapse may still occur in some patients. Clinical outcomes for patients who obtain SVR are excellent, although the patients with cirrhosis are still at a low risk of hepatocellular carcinoma. SN - 1365-2893 UR - https://www.unboundmedicine.com/medline/citation/27453300/Ten_year_follow_up_analysis_of_chronic_hepatitis_C_patients_after_getting_sustained_virological_response_to_pegylated_interferon_α_and_ribavirin_therapy_ L2 - https://doi.org/10.1111/jvh.12574 DB - PRIME DP - Unbound Medicine ER -